J. Loutit

发表

Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: results from a prospectively designed analysis of progression-free survival.

D. Alberts, D. Kirn, R. Alvarez, 2008, Gynecologic oncology.

Levofloxacin Inhalation Solution ( APT-1026 ) in Stable Cystic Fibrosis Patients

R. Fischer, E. Kerem, S. Aaron, 2017 .

A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients.

R. Fischer, E. Kerem, S. Aaron, 2016, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patients.

R. Fischer, E. Kerem, S. Aaron, 2015, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

In Vitro Activity of the Ultrabroad-Spectrum Beta-Lactamase Inhibitor QPX7728 in Combination with Multiple Beta-Lactam Antibiotics against Pseudomonas aeruginosa

M. Castanheira, M. Dudley, Dongxu Sun, 2021, Antimicrobial Agents and Chemotherapy.

Effect of food and antacids on the pharmacokinetics of pirfenidone in older healthy adults.

S. Bhavnani, P. Ambrose, A. Forrest, 2009, Pulmonary pharmacology & therapeutics.

Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection: The TANGO I Randomized Clinical Trial

K. Kaye, J. Vazquez, E. Giamarellos‐Bourboulis, 2018, JAMA.

WS17.6 Phase 3 trial of inhaled levofloxacin (Aeroquin™, MP-376, APT-1026) vs. tobramycin inhalation solution (TIS) in intensively treated CF patients over 6 months

R. Fischer, E. Kerem, S. Aaron, 2013 .

A Phase 2 Study To Evaluate The Safety, Tolerability And Efficacy Of Levofloxacin Inhalation Solution (MP-376) Administered For 5 Days Every 28 Days To Prevent Acute Exacerbations In High Risk COPD Patients

F. Martinez, A. Anzueto, S. Rennard, 2012, ATS 2012.

88 Levofloxacin pharmacokinetics (PK) after administration of MP-376 (Levofloxacin inhalation solution; Aeroquin) in children with cystic fibrosis (CF)

D. C. Griffith, G. Kearns, M. Dudley, 2011 .

Pharmacokinetics and Safety of MP-376 (Levofloxacin Inhalation Solution) in Cystic Fibrosis Subjects

D. C. Griffith, M. Dudley, P. Flume, 2011, Antimicrobial Agents and Chemotherapy.

Pharmacokinetics (PK) of aerosol MP-376 (aeroquin; levofloxacin inhalation solution) in CF patients

D. C. Griffith, M. Dudley, P. Flume, 2010 .

QPX7728, An Ultra-Broad-Spectrum B-Lactamase Inhibitor for Intravenous and Oral Therapy: Overview of Biochemical and Microbiological Characteristics

M. Totrov, M. Dudley, Dongxu Sun, 2021, Frontiers in Microbiology.

Safety and efficacy of prolonged levofloxacin inhalation solution (APT-1026) treatment for cystic fibrosis and chronic Pseudomonas aeruginosa airway infection.

J. Elborn, P. Flume, D. VanDevanter, 2016, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Pharmacokinetic-Pharmacodynamic Target Attainment Analyses as Support for Meropenem-Vaborbactam Dosing Regimens and Susceptibility Breakpoints

D. C. Griffith, S. Cammarata, M. Dudley, 2022, Antimicrobial agents and chemotherapy.

Ex Vivo Characterization of Effects of Renal Replacement Therapy Modalities and Settings on Pharmacokinetics of Meropenem and Vaborbactam

S. Parker, J. Roberts, J. Lipman, 2018, Antimicrobial Agents and Chemotherapy.

Effects of Oritavancin on Coagulation Tests in the Clinical Laboratory

R. Robson, M. Dudley, G. Moeck, 2016, Antimicrobial Agents and Chemotherapy.

Pharmacokinetics, safety, and tolerability of ascending single intravenous doses of oritavancin administered to healthy human subjects.

S. Porter, S. Bhavnani, P. Ambrose, 2004, Diagnostic microbiology and infectious disease.

Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of the β-Lactamase Inhibitor Vaborbactam (RPX7009) in Healthy Adult Subjects

M. Dudley, J. Loutit, E. Morgan, 2016, Antimicrobial Agents and Chemotherapy.

401A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of the Beta-lactamase inhibitor RPX7009 Alone, Meropenem Alone, and both in Combination (Carbavance) TID for 7 days in Healthy Adult Subjects

M. Dudley, J. Loutit, C. Rubino, 2014 .

The Ultrabroad-Spectrum Beta-Lactamase Inhibitor QPX7728 Restores the Potency of Multiple Oral Beta-Lactam Antibiotics against Beta-Lactamase-Producing Strains of Resistant Enterobacterales

M. Dudley, J. Loutit, O. Lomovskaya, 2021, Antimicrobial agents and chemotherapy.

Single Intravenous Dose of Oritavancin for Treatment of Acute Skin and Skin Structure Infections Caused by Gram-Positive Bacteria: Summary of Safety Analysis from the Phase 3 SOLO Studies

M. Dudley, W. O'Riordan, G. Corey, 2018, Antimicrobial Agents and Chemotherapy.

Single-Dose Pharmacokinetics and Safety of Meropenem-Vaborbactam in Subjects with Chronic Renal Impairment

M. Dudley, S. Bhavnani, J. Loutit, 2018, Antimicrobial Agents and Chemotherapy.

Effect and Safety of Meropenem–Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial

R. Wunderink, K. Kaye, J. Solomkin, 2018, Infectious Diseases and Therapy.

Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Vaborbactam and Meropenem Alone and in Combination following Single and Multiple Doses in Healthy Adult Subjects

M. Dudley, S. Bhavnani, J. Loutit, 2018, Antimicrobial Agents and Chemotherapy.

Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Biapenem in Healthy Adult Subjects

M. Dudley, J. Loutit, E. Morgan, 2021, Antimicrobial Agents and Chemotherapy.

Meropenem-Vaborbactam (M-V) Compared With Piperacillin-Tazobactam (P-T) in the Treatment of Adults With Complicated Urinary Tract Infections (cUTI), Including Acute Pyelonephritis (AP) in a Phase 3 Randomized, Double-Blind, Double-Dummy Trial (TANGO 1)

M. Dudley, Shu Zhang, J. Loutit, 2016 .

Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa.

R. Fischer, D. Conrad, P. Flume, 2011, American journal of respiratory and critical care medicine.

Carbapenem-Resistant Enterobacteriaceae Infections: Results From a Retrospective Series and Implications for the Design of Prospective Clinical Trials

R. Wunderink, M. Dudley, G. Daikos, 2017, Open forum infectious diseases.

Interference of Oritavancin on Coagulation Tests as Assessed In vitro and in a Phase 1 Study of Normal Healthy Volunteers

R. Robson, M. Dudley, G. Moeck, 2016 .

WS7.5 Prolonged improvement in lung function and quality of life in cystic fibrosis: a 24-week extension study of levofloxacin nebulization solution (APT-1026) versus tobramycin nebulization solution in stable CF patients with chronic Pseudomonas aeruginosa infection

J. Elborn, P. Flume, J. Loutit, 2014 .

87* Effects of inhaled MP-376 (Aeroquin(tm), levofloxacin inhalation solution) on cystic fibrosis patients with both Staphylococcus aureus (SA) and Pseudomonas aeruginosa (PA) lung infection

D. Conrad, M. Dudley, P. Flume, 2011 .

Effects of inhaled MP-376 (aeroquin, levofloxacin inhalation solution) on lung function in stable cystic fibrosis (CF) patients with chronic Pseudomonas aeruginosa (PA) lung infection

R. Fischer, D. Conrad, P. Flume, 2010 .

Phase 2b Study Of Inhaled MP-376 (Aeroquin, Levofloxacin Inhalation Solution) In Stable Cystic Fibrosis (CF) Patients With Chronic Pseudomonas Aeruginosa (PA) Lung Infection

D. Conrad, P. Flume, J. Loutit, 2010, ATS 2010.

Single-Dose Pharmacokinetics and Safety of Meropenem-Vaborbactam in Subjects with Chronic Renal Impairment

M. Dudley, S. Bhavnani, J. Loutit, 2018, Antimicrobial Agents and Chemotherapy.

The agent of bacillary angiomatosis. An approach to the identification of uncultured pathogens.

S Falkow, D. Relman, T. Schmidt, 1990, The New England journal of medicine.

Population Pharmacokinetics of Meropenem and Vaborbactam Based on Data from Noninfected Subjects and Infected Patients

M. Dudley, S. Bhavnani, P. Ambrose, 2021, Antimicrobial agents and chemotherapy.

Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of the β-Lactamase Inhibitor Vaborbactam (RPX7009) in Healthy Adult Subjects

M. Dudley, J. Loutit, E. Morgan, 2016, Antimicrobial Agents and Chemotherapy.

Single Intravenous Dose of Oritavancin for Treatment of Acute Skin and Skin Structure Infections Caused by Gram-Positive Bacteria: Summary of Safety Analysis from the Phase 3 SOLO Studies

P. Altmeyer, G. Rahav, D. Zeltser, 2018, Antimicrobial Agents and Chemotherapy.

A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patients.

R. Fischer, E. Kerem, S. Aaron, 2015, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa.

R. Fischer, D. Conrad, P. Flume, 2011, American journal of respiratory and critical care medicine.